◎ Sugi Atlas

Atlas / Drug / Etanercept

Etanercept

drug
On this page

Also known as BenepaliChs-0214DavictrelDwp-422EnbrelEnia-11ErelziEtanercept (enbrel)Etanercept biosimilar (gp-2015)Etanercept biosimilar (sandoz)Etanercept biosimilar (sb-4)Etanercept szzsEtanercept ykroEtanercept-szzsEtanercept-ykroEticovoGP-2015GP2015GP2015C

Summary

Etanercept (CHEMBL1201572) is an approved protein (ATC L04AB01); indicated across 55 conditions including ankylosing spondylitis and juvenile idiopathic arthritis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Protein
  • ATC class: L04AB01
  • Indications: 55 conditions
  • Clinical trials: 339

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201572
NameEtanercept
TypeProtein
Max phase4
ATCL04AB01

Also known as: Benepali, Chs-0214, Davictrel, Dwp-422, Enbrel, Enia-11, Erelzi, Etanercept, Etanercept (enbrel), Etanercept biosimilar (gp-2015), Etanercept biosimilar (sandoz), Etanercept biosimilar (sb-4)

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

55 indications (9 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
ankylosing spondylitis4MONDO:0005306EFO:0003898
juvenile idiopathic arthritis4MONDO:0011429EFO:0002609
psoriasis4MONDO:0005083EFO:0000676
rheumatoid arthritis4MONDO:0008383EFO:0000685
psoriatic arthritis4MONDO:0011849EFO:0003778
immune system disorder4MONDO:0005046EFO:0000540
spondylitis4MONDO:0003937MONDO:0003937
spondyloarthropathy4MONDO:0005095EFO:0000706
pneumonia3MONDO:0005249EFO:0003106
Stevens-Johnson syndrome3MONDO:0018229EFO:0004276
polymyalgia rheumatica3MONDO:0019735EFO:0008518
arthritic joint disease3MONDO:0005578MONDO:0024280
type 1 diabetes mellitus3MONDO:0005147MONDO:0005147
dermatomyositis2MONDO:0016367EFO:0000398
chronic kidney disease2MONDO:0005300EFO:0003884
leukemia2MONDO:0005059EFO:0000565
ischemia reperfusion injury2MONDO:0005203EFO:0002687
Kawasaki disease2MONDO:0012727EFO:0004246
lichen planus2MONDO:0006572EFO:1000726
hidradenitis suppurativa2MONDO:0006559EFO:1000710
metabolic syndrome X2MONDO:0011565EFO:0000195
chronic obstructive pulmonary disease2MONDO:0005002EFO:0000341
Sjogren syndrome2MONDO:0010030EFO:0000699
vitiligo2MONDO:0008661EFO:0004208
pemphigus vulgaris2MONDO:0008219EFO:0004719
temporomandibular joint disorder2MONDO:0005473EFO:0005279
granulomatosis with polyangiitis2MONDO:0012105EFO:0005297
lupus nephritis2MONDO:0005556EFO:0005761
histiocytosis2MONDO:0002637HP:0100727
synovitis2MONDO:0002400EFO:0008997
pulmonary fibrosis2MONDO:0002771EFO:0009448
stomatitis2MONDO:0004842EFO:0009688
cutaneous lupus erythematosus2MONDO:0005282EFO:0003834
radiculopathy2MONDO:0002959MONDO:0002959
graft versus host disease2MONDO:0013730MONDO:0013730
Alzheimer disease2MONDO:0004975MONDO:0004975
asthma2MONDO:0004979MONDO:0004979
SAPHO syndrome2MONDO:0019266EFO:1001164
subarachnoid hemorrhage1MONDO:0005099EFO:0000713
sciatica1MONDO:0024333HP:0011868
B-cell chronic lymphocytic leukemia1MONDO:0004948EFO:0000095
myelodysplastic syndrome1MONDO:0018881EFO:0000198
neoplasm1MONDO:0005070EFO:0000616
HIV infectious disease1MONDO:0005109EFO:0000764
persian gulf syndrome1MONDO:0005907EFO:0007430
inclusion body myositis0MONDO:0007827EFO:0007323
Fanconi anemia0MONDO:0019391MONDO:0019391

8 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 339.

Phase distribution

PhaseTrials
PHASE491
PHASE378
Not specified73
PHASE245
PHASE126
PHASE1/PHASE212
PHASE2/PHASE311
EARLY_PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03976245PHASE4RECRUITINGAdvanced Therapeutics in Rheumatoid Arthritis (RA)
NCT06707194PHASE4RECRUITINGEffect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis
NCT07352566PHASE4NOT_YET_RECRUITINGUtilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT00094341PHASE4COMPLETEDPreference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes
NCT00099554PHASE4COMPLETEDEffectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)
NCT00110981PHASE4COMPLETEDUtilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis
NCT00115219PHASE4COMPLETEDEvaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)
NCT00127842PHASE4COMPLETEDREPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)
NCT00132418PHASE4COMPLETEDStudy of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders
NCT00133315PHASE4COMPLETEDTNFalfa Blocking Treatment of Spondylarthropathies
NCT00161655PHASE4COMPLETEDStudy Evaluating Etanercept and Methotrexate in Plaque Psoriasis
NCT00195494PHASE4COMPLETEDStudy Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis
NCT00195507PHASE4COMPLETEDStudy Evaluating Etanercept in the Treatment of Subjects With Psoriasis
NCT00245960PHASE4COMPLETEDStudy Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
NCT00247962PHASE4COMPLETEDStudy Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis
NCT00252668PHASE4COMPLETEDStudy Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects
NCT00259610PHASE4COMPLETEDTreatment of Early Aggressive Rheumatoid Arthritis (TEAR)
NCT00332332PHASE4COMPLETEDCanadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis
NCT00346294PHASE4COMPLETEDAn Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis
NCT00410046PHASE4COMPLETEDExtension Study Evaluating Etanercept in Ankylosing Spondylitis
NCT00420238PHASE4COMPLETEDStudy Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis
NCT00420303PHASE4COMPLETEDStudy Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy
NCT00422227PHASE4COMPLETEDStudy Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region
NCT00432406PHASE4COMPLETEDTumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis
NCT00444340PHASE4COMPLETEDAn Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis
NCT00458185PHASE4COMPLETEDStudy Evaluating Etanercept in Patients With Ankylosing Spondylitis
NCT00546533PHASE4COMPLETEDStudy Evaluating the Efficacy and Safety of Etanercept
NCT00565409PHASE4COMPLETEDStudy Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis
NCT00581100PHASE4COMPLETEDEffects of Etanercept on Nail Psoriasis and Plaque Psoriasis
NCT00581165PHASE4COMPLETEDStudy Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept
NCT00581555PHASE4COMPLETEDEvaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy
NCT00640393PHASE4COMPLETEDSafety and Efficacy of Combining nbUVB to Etanercept in Patients
NCT00654368PHASE4COMPLETEDCAMEO: Canadian Methotrexate and Etanercept Outcome Study
NCT00663052PHASE4COMPLETEDStudy Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis
NCT00706797PHASE4TERMINATEDStudy Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects
NCT00768053PHASE4COMPLETEDEvaluation of EULAR-RAID Score in Rheumatoid Arthritis Patients
NCT00783536PHASE4WITHDRAWNA Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Treatment of Rheumatoid Arthritis
NCT00791765PHASE4COMPLETEDModerate to Severe Plaque Psoriasis With Scalp Involvement
NCT00796705PHASE4TERMINATEDSwitching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)
NCT00832364PHASE4WITHDRAWNTrial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 15

This page pulls from 15 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem